ArticlePloS one2025
Platelet-rich plasma: A promising therapy for mitigating sperm oxidative stress and mitochondrial dysfunction in subfertile men.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Platelet-Rich Plasma Dose and Application Strategy on Post-Thaw Spermatological Parameters in Goat Semen.Veterinary sciences · 2026Article
- Platelet-Rich Plasma in Sperm Processing for Assisted Reproductive Technology: Molecular Mechanisms, Clinical Applications, and Future Directions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP) is a pioneering therapy widely used in various medical fields, showing promising outcomes. However, its impact on human sperm quality remains poorly explored among emerging therapies. This study aims to investigate the effect of autologous PRP supplementation on oxidative stress levels and mitochondrial activity in human sperm. PRP was freshly prepared from venous blood and added to each ejaculated semen sample at different concentrations of 2%, 5%, and 10%. Reactive oxygen species (ROS) in spermatozoa were measured after 24 hours of incubation at 37° (5% CO2), using nitro-blue tetrazolium (NBT) test. The MTT test was used to measure the mitochondrial succinate deshydrogenase activity. A total of 180 semen samples were obtained from 15 patients. The supplementation with PRP significantly reduced the reactive oxidative species levels and improved mitochondrial activity in spermatozoa. The level of oxidative stress in sperm was significantly decreased after 24h of incubation with PRP at 2% (p = 0.001), 5% (p = 0.001) and 10% (p = 0.001) when compared to the control group. The succinate dehydrogenase activity was enhanced in the three groups when compared to the control group. It increased from 0.667 ± 0.313 to 0.952 ± 0.499 (p = 0.018), 1.201 ± 0.657 (p = 0.002) and 1.159 ± 0.607 (p = 0.001) after incubation with 2%, 5% and 10% of PRP, respectively. This study has shown that PRP supplementation could be a promising tool to enhance sperm quality against oxidative stress and mitochondrial dysfunction. These findings could be a starting point to investigate the usefulness of PRP in ART procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.